Ersodetug for tumor-associated hyperinsulinism (Phase 3 pivotal, single-arm)

Phase 3, open-label, single-arm trial of ersodetug in hyperinsulinism (HI), sponsored by Rezolute, Inc. Primary endpoints: Proportion of participants with clinically meaningful reduction in glucose infusion rate from baseline, OLE: Long-term glycemic efficacy of ersodetug and 1 more. Planned start Mar 2026; status: authorised.